Details of the Drug Combination

General Information of Drug Combination (ID: DC9ORXH)

Drug Combination Name
Phensuximide Brincidofovir
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Phensuximide   DMFGLXB Brincidofovir   DMS0PND
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 2.78
Bliss Independence Score: 2.78
Loewe Additivity Score: 4.28
LHighest Single Agent (HSA) Score: 4.36

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Phensuximide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7612).
4 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.